Aclarion, INC. (ACONW) — SEC Filings

Overview

Aclarion, INC. (ACONW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 12, 2025: Aclarion, Inc. reported a net loss of $1,706,294 for the three months ended September 30, 2025, compared to a net loss of $1,366,176 for the same period in 2024, representing a 24.9% increase in loss. For the nine months ended September 30, 2025, the net loss was $5,344,487, up from $5,003,355 in 20

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 4 bearish, 45 neutral, 1 mixed. The dominant filing sentiment for Aclarion, INC. is neutral.

Filing Type Overview

Aclarion, INC. (ACONW) has filed 6 10-Q, 29 8-K, 4 DEF 14A, 2 10-K, 2 S-1/A, 2 S-1, 2 SC 13G/A, 2 SC 13G, 1 8-K/A with the SEC between Feb 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

• Aclarion's Losses Widen Amid Soaring Expenses, Despite Capital Influx — 10-Q · Nov 12, 2025 Risk: high
  Aclarion, Inc. reported a net loss of $1,706,294 for the three months ended September 30, 2025, compared to a net loss of $1,366,176 for the same period in 2024
• Aclarion, Inc. Files 8-K for Material Definitive Agreement — 8-K · Oct 14, 2025 Risk: medium
  Aclarion, Inc. entered into a material definitive agreement on October 13, 2025. The company, formerly known as Nocimed, Inc., is incorporated in Delaware and h
• Aclarion, Inc. Files 8-K with Material Agreements and Officer Changes — 8-K · Sep 3, 2025 Risk: medium
  Aclarion, Inc. filed an 8-K on September 3, 2025, reporting on several key events as of September 2, 2025. These include entering into a material definitive agr
• Aclarion's Cash Surges 2700% Amidst Widening Losses — 10-Q · Aug 14, 2025 Risk: high
  Aclarion, Inc. (ACONW) reported a significant increase in cash and cash equivalents to $12,825,657 as of June 30, 2025, up from $453,661 on December 31, 2024, p
• Aclarion, Inc. Files 8-K on Security Holder Votes — 8-K · Jul 21, 2025 Risk: low
  Aclarion, Inc. filed an 8-K on July 21, 2025, to report on matters submitted to a vote of its security holders. The filing does not contain details about the sp
• Aclarion, Inc. Files 8-K: Key Corporate Updates — 8-K · Jul 7, 2025 Risk: low
  Aclarion, Inc. filed an 8-K on July 7, 2025, reporting on matters submitted to a vote of security holders, Regulation FD disclosures, and financial statements.
• Aclarion, Inc. Reports Director and Officer Changes — 8-K · Jun 20, 2025 Risk: medium
  Aclarion, Inc. filed an 8-K on June 20, 2025, reporting changes effective June 16, 2025. The filing covers the departure of directors or certain officers, elect
• Aclarion, Inc. Files Q1 2025 10-Q — 10-Q · May 15, 2025 Risk: low
  Aclarion, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly Nocimed, Inc., is incorporated in Delaware and operates in the medical
• Aclarion Inc. Files Definitive Proxy Statement — DEF 14A · May 13, 2025 Risk: low
  Aclarion, Inc. filed its Definitive Proxy Statement (DEF 14A) on May 13, 2025, for its annual meeting on July 7, 2025. The company, formerly known as Nocimed, I
• Aclarion, Inc. Files 8-K — 8-K · Apr 23, 2025 Risk: low
  Aclarion, Inc. filed an 8-K on April 23, 2025, reporting on Regulation FD disclosures and financial statements. The company, formerly Nocimed, Inc., is incorpor
• Aclarion, Inc. Files 2024 10-K — 10-K · Apr 9, 2025 Risk: low
  Aclarion, Inc. filed its 10-K for the fiscal year ending December 31, 2024, on April 9, 2025. The company, formerly known as Nocimed, Inc. until February 26, 20
• Aclarion, Inc. Files 8-K on Security Holder Rights — 8-K · Mar 28, 2025 Risk: low
  Aclarion, Inc. filed an 8-K on March 28, 2025, reporting material modifications to the rights of security holders and amendments to its articles of incorporatio
• Aclarion, Inc. Files 8-K Report — 8-K · Mar 13, 2025 Risk: low
  On March 13, 2025, Aclarion, Inc. filed an 8-K report. The filing indicates that the company's principal executive offices are located at 8181 Arista Place, Sui
• Aclarion, Inc. Files 8-K on Security Holder Vote — 8-K · Mar 6, 2025 Risk: medium
  Aclarion, Inc. filed an 8-K on March 6, 2025, reporting on a matter submitted to a vote of its security holders on March 5, 2025. The filing does not disclose t
• Aclarion, Inc. Files 8-K with Shareholder Votes and Financials — 8-K · Feb 28, 2025 Risk: low
  Aclarion, Inc. filed an 8-K on February 28, 2025, reporting on matters submitted to a vote of security holders, Regulation FD disclosures, and financial stateme
• Aclarion, Inc. Files Definitive Proxy Statement — DEF 14A · Feb 3, 2025 Risk: low
  Aclarion, Inc. filed a Definitive Proxy Statement (DEF 14A) on February 3, 2025, for its fiscal year ending December 31, 2024. The filing, which does not requir
• Aclarion, Inc. Files 8-K for Material Agreement — 8-K · Jan 31, 2025 Risk: medium
  Aclarion, Inc. filed an 8-K on January 31, 2025, reporting a material definitive agreement entered into on January 30, 2025. The filing also includes Regulation
• Aclarion, Inc. Files 8-K on Security Holder Rights and Bylaws — 8-K · Jan 30, 2025 Risk: medium
  Aclarion, Inc. filed an 8-K on January 30, 2025, reporting events that occurred on January 29, 2025. The filing indicates material modifications to the rights o
• Aclarion, Inc. Files 8-K for Material Agreement — 8-K · Jan 17, 2025 Risk: medium
  On January 15, 2025, Aclarion, Inc. entered into a material definitive agreement. The filing also includes financial statements and exhibits related to this agr
• Aclarion, Inc. Files S-1/A Amendment — S-1/A · Jan 10, 2025 Risk: medium
  Aclarion, Inc. filed an S-1/A amendment on January 10, 2025, detailing its business operations as a medical laboratory services provider. The company, formerly
• Aclarion, Inc. Files 8-K for Material Agreement — 8-K · Jan 6, 2025 Risk: medium
  Aclarion, Inc. filed an 8-K on January 6, 2025, reporting a material definitive agreement entered into on January 3, 2025. The filing also includes Regulation F
• Aclarion, Inc. Files 8-K on Shareholder Votes — 8-K · Jan 3, 2025 Risk: low
  Aclarion, Inc. filed an 8-K on January 3, 2025, reporting on matters submitted to a vote of security holders as of December 31, 2024. The filing details the com
• Aclarion, Inc. Files S-1/A Amendment — S-1/A · Dec 26, 2024 Risk: medium
  Aclarion, Inc. filed an S-1/A amendment on December 26, 2024, for its registration statement (No. 333-283724). The company, formerly known as Nocimed, Inc. unti
• Aclarion, Inc. Files for IPO — S-1 · Dec 11, 2024 Risk: medium
  Aclarion, Inc. filed an S-1 form on December 11, 2024, indicating its intention to go public. The company, formerly known as Nocimed, Inc., is based in Broomfie
• Aclarion, Inc. Files Definitive Proxy Statement — DEF 14A · Dec 2, 2024 Risk: low
  Aclarion, Inc. filed a Definitive Proxy Statement (DEF 14A) on December 2, 2024, for its fiscal year ending December 31, 2024. The filing concerns the company's
• Aclarion, Inc. Files 8-K: Material Agreement & Equity Sales — 8-K · Nov 27, 2024 Risk: medium
  On November 27, 2024, Aclarion, Inc. filed an 8-K report detailing a material definitive agreement. The filing also covers unregistered sales of equity securiti
• Aclarion, Inc. Files 10-Q for Q3 2024 — 10-Q · Nov 14, 2024 Risk: low
  Aclarion, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Nocimed, Inc., is incorporated in Delaware and operates i
• SC 13G/A Filing — SC 13G/A · Nov 13, 2024
• Aclarion, Inc. Files for IPO — S-1 · Oct 25, 2024 Risk: medium
  Aclarion, Inc. filed an S-1 form on October 25, 2024, indicating its intention to go public. The company, formerly known as Nocimed, Inc., is based in Broomfiel
• Aclarion, Inc. Faces Delisting Concerns — 8-K · Oct 11, 2024 Risk: high
  Aclarion, Inc. filed an 8-K on October 11, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The earliest event
• Aclarion, Inc. Files 8-K: Material Agreement, Equity Sales — 8-K · Oct 1, 2024 Risk: medium
  Aclarion, Inc. filed an 8-K on October 1, 2024, reporting on events as of September 30, 2024. The filing indicates a material definitive agreement, unregistered
• Aclarion, Inc. Files 8-K for Material Definitive Agreement — 8-K · Sep 24, 2024 Risk: medium
  Aclarion, Inc. announced on September 24, 2024, that it entered into a Material Definitive Agreement. The filing does not provide specific details about the agr
• Aclarion, Inc. Files 8-K for Security Holder Vote — 8-K · Sep 23, 2024 Risk: medium
  On September 23, 2024, Aclarion, Inc. filed an 8-K report to announce the submission of matters to a vote of its security holders. The filing does not disclose
• SC 13G Filing — SC 13G · Sep 5, 2024
• Aclarion, Inc. Reports Material Definitive Agreement — 8-K · Aug 29, 2024 Risk: medium
  Aclarion, Inc. entered into a material definitive agreement on August 27, 2024, related to the unregistered sale of equity securities. The company, formerly kno
• Aclarion Inc. Files Definitive Proxy Statement — DEF 14A · Aug 26, 2024 Risk: low
  Aclarion, Inc. filed a Definitive Proxy Statement (DEF 14A) on August 26, 2024, for the fiscal year ending December 31, 2024. The filing concerns the company's
• Aclarion, Inc. Faces Delisting Concerns — 8-K · Aug 23, 2024 Risk: high
  Aclarion, Inc. filed an 8-K on August 23, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The company was formerly known a
• Aclarion, Inc. Files 8-K for Equity Sales and Financials — 8-K · Aug 16, 2024 Risk: medium
  On August 14, 2024, Aclarion, Inc. entered into a material definitive agreement related to unregistered sales of equity securities. The filing also includes fin
• Aclarion, Inc. Files Q2 2024 10-Q Report — 10-Q · Aug 14, 2024 Risk: medium
  Aclarion, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as Nocimed, Inc., is based in Broomfield, CO. The filing covers t
• Aclarion, Inc. Files 8-K/A Amendment — 8-K/A · Aug 13, 2024 Risk: low
  Aclarion, Inc. filed an amendment (8-K/A) on August 13, 2024, to a previous report dated August 12, 2024. The amendment corrects a hyperlink within the original
• Aclarion, Inc. Files 8-K for Material Agreement — 8-K · Aug 12, 2024 Risk: medium
  On August 12, 2024, Aclarion, Inc. entered into a material definitive agreement. The filing also includes financial statements and exhibits related to this agre
• Aclarion, Inc. Files Material Definitive Agreement 8-K — 8-K · Jun 26, 2024 Risk: medium
  On June 26, 2024, Aclarion, Inc. filed an 8-K report detailing a material definitive agreement. The company, formerly known as Nocimed, Inc., is incorporated in
• Aclarion, Inc. Files 8-K with Corporate Updates — 8-K · Jun 18, 2024 Risk: low
  Aclarion, Inc. filed an 8-K on June 18, 2024, reporting events that occurred on June 12, 2024. The filing indicates amendments to its Articles of Incorporation
• Aclarion, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 15, 2024 Risk: low
  Aclarion, Inc. (ACONW) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Aclarion, Inc. filed its quarterly report (10-Q) for the period ending Marc
• Aclarion, Inc. Files 8-K for Regulation FD Disclosure — 8-K · Apr 29, 2024 Risk: low
  Aclarion, Inc. filed an 8-K on April 29, 2024, reporting an event that occurred on April 26, 2024. The filing is categorized under Regulation FD Disclosure. The
• Aclarion Faces Delisting Concerns — 8-K · Apr 12, 2024 Risk: high
  Aclarion, Inc. filed an 8-K on April 12, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The earliest event re
• SC 13G/A Filing — SC 13G/A · Mar 29, 2024
• Aclarion, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 28, 2024 Risk: low
  Aclarion, Inc. (ACONW) filed a Annual Report (10-K) with the SEC on March 28, 2024. Aclarion, Inc. filed its 10-K report for the fiscal year ending December 31,
• SC 13G Filing — SC 13G · Mar 6, 2024
• Aclarion Files 8-K on Material Definitive Agreement — 8-K · Feb 27, 2024 Risk: medium
  Aclarion, Inc. filed an 8-K on February 27, 2024, reporting the entry into a Material Definitive Agreement and other events. The filing indicates the company's

Risk Profile

Risk Assessment: Of ACONW's 46 recent filings, 5 were flagged as high-risk, 22 as medium-risk, and 19 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Aclarion, INC.'s most recent 10-Q filing (Nov 12, 2025):

• Revenue: $57,251
• Net Income: -$5,344,487
• EPS: N/A
• Debt-to-Equity: 0.06
• Cash Position: $11,341,336
• Operating Margin: -8837.5%
• Total Assets: $13,200,298
• Total Debt: $699,747

Key Executives

• John Lorbiecki

Industry Context

Aclarion operates in the healthcare technology sector, likely focusing on diagnostic or therapeutic solutions. This industry is characterized by high R&D investment, long development cycles, and significant regulatory hurdles. Companies in this space often rely on substantial funding rounds to support innovation and market entry, facing competition from established players and other emerging technologies.

Top Tags

corporate-governance (11) · material-agreement (8) · filing (6) · financials (6) · corporate-filing (4) · 10-Q (4) · proxy-statement (4) · regulatory-filing (4) · ipo (4) · material-definitive-agreement (4)

Key Numbers

• Net loss for Q3 2025: $1,706,294 — Increased from $1,366,176 in Q3 2024, a 24.9% increase.
• Net loss for YTD Q3 2025: $5,344,487 — Increased from $5,003,355 in YTD Q3 2024, a 6.8% increase.
• Cash and cash equivalents: $11,341,336 — As of September 30, 2025, a significant increase from $453,661 at December 31, 2024.
• Proceeds from public offering: $14,554,545 — Cash provided by financing activities in YTD Q3 2025.
• Proceeds from Registered Direct offerings: $5,167,927 — Cash provided by financing activities in YTD Q3 2025.
• Sales and marketing expense for Q3 2025: $632,409 — Increased 171.7% from $232,775 in Q3 2024.
• Sales and marketing expense for YTD Q3 2025: $1,278,759 — Increased 100.2% from $638,869 in YTD Q3 2024.
• Research and development expense for Q3 2025: $302,037 — Increased 54.3% from $195,797 in Q3 2024.
• Revenue for YTD Q3 2025: $57,251 — Increased from $35,492 in YTD Q3 2024.
• Common shares outstanding: 582,371 — As of September 30, 2025, after two reverse stock splits.
• SEC File Number: 001-41358 — Identifies the company's filings with the SEC.
• IRS Employer Identification No.: 47-3324725 — Company's tax identification number.
• Quarterly Revenue: $19,319 — Increased 76% from $10,971 in Q2 2024
• Six-Month Revenue: $38,309 — Increased 81% from $21,085 in H1 2024
• Six-Month Net Loss: $(3.64M) — Slightly widened from $(3.63M) in H1 2024

Related Companies

ACON · ACRN

Frequently Asked Questions